Nicola J. Curtin

Framlington Place
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia.

Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia.

Journal: Free radical biology & medicine

Published: October 28, 2024

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Journal: Nature reviews. Drug discovery

Published: September 17, 2024

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

Journal: British journal of cancer

Published: August 19, 2024

Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 28, 2024

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers.

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers.

Journal: Journal of cellular and molecular medicine

Published: June 18, 2024

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Journal: Oncotarget

Published: February 22, 2024

The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.

The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.

Journal: British journal of pharmacology

Published: September 15, 2023

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.

Journal: British journal of cancer

Published: August 03, 2023

25 years of ERMM.

25 years of ERMM.

Journal: Expert reviews in molecular medicine

Published: April 18, 2023

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Journal: Cancers

Published: September 30, 2022

Targeting the DNA damage response for cancer therapy.

Targeting the DNA damage response for cancer therapy.

Journal: Biochemical Society transactions

Published: September 26, 2022

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Journal: Cancers

Published: July 26, 2022

Showing 1-12 of 86

Last Updated: 09/26/2026